Everett Harris & Co. CA decreased its position in Edwards Lifesciences Corporation (NYSE:EW) by 0.4% during the second quarter, Holdings Channel reports. The institutional investor owned 54,478 shares of the medical research company’s stock after selling 240 shares during the period. Everett Harris & Co. CA’s holdings in Edwards Lifesciences Corporation were worth $6,441,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in EW. YorkBridge Wealth Partners LLC acquired a new position in shares of Edwards Lifesciences Corporation during the first quarter worth about $110,000. NEXT Financial Group Inc increased its position in shares of Edwards Lifesciences Corporation by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock worth $115,000 after buying an additional 500 shares during the period. Shine Investment Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences Corporation during the second quarter worth about $126,000. Cornerstone Advisors Inc. increased its position in shares of Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after buying an additional 219 shares during the period. Finally, Alexandria Capital LLC increased its position in shares of Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after buying an additional 19 shares during the period. 84.67% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Corporation (NYSE EW) opened at 115.57 on Thursday. Edwards Lifesciences Corporation has a 52-week low of $81.12 and a 52-week high of $121.75. The stock has a market cap of $24.40 billion, a PE ratio of 35.05 and a beta of 0.63. The firm has a 50-day moving average price of $116.68 and a 200 day moving average price of $105.85.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company had revenue of $842 million for the quarter, compared to the consensus estimate of $839.16 million. During the same quarter in the previous year, the business earned $0.76 EPS. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. Equities analysts anticipate that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/17/everett-harris-co-ca-has-6-44-million-stake-in-edwards-lifesciences-corporation-ew.html.

A number of equities analysts recently issued reports on EW shares. Vetr downgraded Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating and set a $124.67 price target for the company. in a report on Monday, May 15th. Zacks Investment Research upgraded Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $125.00 price objective for the company in a research note on Monday, May 22nd. Goldman Sachs Group, Inc. (The) initiated coverage on Edwards Lifesciences Corporation in a research note on Tuesday, May 16th. They issued a “conviction-buy” rating and a $138.00 price objective for the company. Canaccord Genuity reiterated a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Finally, Barclays PLC boosted their price objective on Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the company an “equal weight” rating in a research note on Thursday, July 27th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $121.13.

In other news, VP Donald E. Bobo, Jr. sold 25,000 shares of the business’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $116.00, for a total transaction of $2,900,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $118.05, for a total value of $3,883,845.00. The disclosure for this sale can be found here. Insiders sold a total of 171,912 shares of company stock worth $19,892,370 in the last three months. Company insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.